COMPANY PROFILE / #2411
Hurdle (Decision/Risk Analysis)
London, United KingdomVenture Capital-Backed
OVERVIEW
Developer of a diagnostic platform designed to facilitate better care, operational optimization, and personalized health interventions. The company's platform utilizes artificial intelligence to analyze diagnostic data and offer personalized and accurate diagnostics, enabling healthcare providers to improve accuracy, efficiency, scalability, and patient care.
已融资17.17
最新估值54.30
员工数33
成立年份2017
公司概况
- Companies
- Hurdle (Decision/Risk Analysis)
- Description
- Developer of a diagnostic platform designed to facilitate better care, operational optimization, and personalized health interventions. The company's platform utilizes artificial intelligence to analyze diagnostic data and offer personalized and accurate diagnostics, enabling healthcare providers to improve accuracy, efficiency, scalability, and patient care.
- Website
- www.hurdle.bio
- HQ Location
- London, United Kingdom
- Year Founded
- 2017
- Keywords
- data driven insights, diagnostic management, diagnostics infrastructure, health data analytics, healthcare optimization, medical diagnostics technology
- Competitors
- DarioHealth, ixLayer, Cognoa, Mevoked, Blue Mesa Health, MEMOTEXT, Big Health, Tridiuum, NovuHealth, LifeWIRE, Alma, Pager Health, Spring Health, Glooko, Unmind, Starling Minds, Lark, Noom, Welldoc, myStrength, Sanvello, biomodal, American Well, LetsGetChecked, Everlywell, Welltok, Thriva
- Ownership Status
- Privately Held (backing)
- Company Financing Status
- Venture Capital-Backed
融资与估值
- Total Raised
- 17.17
- First Financing Date
- 22-Dec-2017
- First Financing Size
- 0.10
- First Financing Valuation
- 1.20
- Last Financing Date
- 26-Mar-2025
- Last Financing Deal Type
- Later Stage VC
- Last Financing Size
- 7.92
- Last Financing Valuation
- 54.30
- Last Financing Status
- Completed
- Last Known Valuation
- 54.30
- Last Known Valuation Date
- 26-Mar-2025
- Last Known Valuation Deal Type
- Later Stage VC
- Valuation Estimate
- 104.38
- Valuation Estimate Growth Rate
- 92.23%
- Active Investors
- Anthemis, Cola Blanca Investments, Expedite Capital, Laurence Garrett, Outsized Ventures, RebelBio, Samos Investments, SOSV, Start Capital
- # Active Investors
- 9
- Acquirers
- —
团队与联系人
- Employees
- 33
- Employee Growth %
- -23.26%
- Employee History
- 2024: 33, 2023: 43, 2022: 36 E, 2021: 28, 2020: 12, 2019: 8, 2018: 5
- Primary Contact
- Gordon McCulloch
- Primary Contact Title
- Chief Financial Officer
- Primary Contact Email
- gordon.mcculloch@chronomics.com
- Primary Contact Phone
- —
增长与经营
- Revenue
- —
- Revenue Growth %
- —
- Growth Rate
- 0.77%
- Growth Rate % Change
- —
- Growth Rate Percentile
- 96
- Size Multiple
- 9.04x
- Size Multiple % Change
- 0.00%
- Size Multiple Change
- 0.00x
- Size Multiple Percentile
- 92
- Majestic Referring Domains
- 235
- SimilarWeb Unique Visitors
- 373
- SimilarWeb Unique Visitors Change
- 40
- SimilarWeb Growth Rate
- —
- SimilarWeb Growth Rate Percentile
- —
- Success Probability Over Time – 1 Year
- 5%
- Success Probability Over Time – 3 Year
- 15%
- Success Probability Over Time – 5 Year
- 25%
记录来源：public.companies · 原始序号 #2411 · 所有字段均按数据库原值展示。